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Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diag-
nosed behavioral disorders among children in the United States, affecting approximately 
3%-5% of all school-aged children (American Psychiatric Association, 1994; Barkley, 
1998). ADHD is characterized by developmentally inappropriate levels of inattention, 
hyperactivity, and impulsivity (APA, 1994). Although the ways of characterizing the dis-
order have changed somewhat throughout the years , the current classification system rec-
ognizes three empirically derived subtypes of ADHD: predominantly inattentive type, pre-
dominantly hyperactive-impulsive type, and combined type (Lahey et al., 1994). 
Given the demonstrated academic and social outcomes associated with ADHD, the 
occurrence of this disorder in school-aged children represents a significant public health 
concern. For example, studies of co-occurring problems suggest that children diagnosed 
with ADHD also are more likely to be diagnosed with oppositional defiant disorder 
(ODD), conduct disorder (CD), depression and other mood problems, anxiety problems, 
and tics (see Barkley, 1998; and Biederman, Wilens, & Spencer, 1999, for reviews of the 
impairment associated with ADHD). 
When studied across time, children diagnosed with ADHD are at higher risk for con-
tinuing to have learning, behavioral, and emotional problems throughout childhood and 
adolescence (e.g., Barkley, Fischer, Edelbrock, & Smallish, 1991). Compared to controls, 
adults who were diagnosed with ADHD as children receive fewer years of formal school-
ing, achieve lower overall occupational status, and are more likely to have a range of psy-
chiatric problems as adults, such as antisocial personality disorder and non-alcohol sub-
stance abuse (e.g., Mannuzza, Klein, Bessler, Malloy, & LaPadula, 1998). Further, 
children with ADHD have been shown to have difficulty with social interactions with 
peers (e.g., Flicek, 1992) and family members (e.g., Barkley et al., 1991; Fletcher, Fischer, 
Barkley, & Smallish, 1996), especially when co-occurring conditions such as learning 
problems or ODD are present. 
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Given the potential for these adverse outcomes, effective 
treatment of ADHD is critical. Controlled studies examining 
the efficacy of different kinds of interventions have been 
conducted since at least the early 1960s, with three general 
approaches to treating ADHD receiving the most attention: 
1. Pharmacological approaches 
2. Behavioral/psychosocial approaches 
3. A combination of behavioral and psychosocial 
approaches. 
The vast majority of the scientific evidence suggests that 
effective treatment for children with ADHD consists of low-
to-moderate doses of stimulant medication, such as 
methylphenidate (Ritalin) or d-amphetamine (Dexedrine) 
(see Swanson et al., 1993, for a review). 
More recently, results of the largest trial ever conducted 
with children having ADHD became available through the 
Multimodal Treatment of ADHD (MTA) study sponsored by 
the National Institute of Mental Health. This project demon-
strated that, compared to standard community-based care 
and a structured behavioral intervention, a carefully man-
aged protocol of stimulant medication or a combination of 
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medication and behavioral intervention led to the greatest 
reductions in ADHD symptoms across participants (MTA 
Cooperative Group, 1999). 
Although this study reported that tpe combination of 
medication plus behavioral intervention did not reduce 
ADHD symptoms more than the medication protocol alone, 
the combined treatment was associated with lower effective 
doses of medication. Moreover, compared to the medication 
management intervention, both the combined and the 
behavioral intervention received significantly higher parent 
satisfaction scores at the end of the 14-month trial. The 
behavioral intervention was also equal in efficacy, though 
not superior to medication management for some aspects of 
problem behavior often observed in children with ADHD, 
such as oppositional/aggressive behavior, social skills, par-
ent-child relations, and academic achievement (MTA Coop-
erative Group, 1999). 
Although the MTA collaborative study is the largest and 
longest trial of medication with children with ADHD, its 
duration (14 months) is still relatively short in comparison 
to the duration of time that many children are prescribed the 
medications. As such, information regarding the long-term 
risks and benefits of using medications with children is 
limited. 
The widespread use of stimulant medication in treating 
childhood behavior problems has been accompanied by sub-
stantial controversy, much of which has been generated in 
the popular media and outside of the scientific literature. In 
particular, the long-term safety and efficacy of the use of 
chronic medication has been called into question. For exam-
ple, chronic use may increase the risk for substance use and 
abuse later in life. Although at least one study found the 
opposite to be true (Biederman, Wilens, Mick, Spencer, & 
Faraone, 1999), the issue of whether the use of stimulants 
has significant long-term effects, either positive or negative, 
is yet to be resolved conclusively. 
Another controversial issue pertaining to the use of stim-
ulant drugs (and other classes of drugs) is the growing fre-
quency with which these are prescribed for behavioral prob-
lems in children and adolescents. One study documented the 
increased use of psychotropic medications in children, espe-
cially those younger than 6 years of age (Zito et al., 2000). 
This study reported 1.7-3.1-fold increases in the use of med-
ication (most often Ritalin) for the treatment of behavior 
problems in preschool children. The causes for these 
increases have yet to be identified conclusively. 
A rise in use of medication alone is not necessarily cause 
for alarm or prima facie evidence of overdiagnosis or over-
medication. An estimated 6%-9% of preschool children 
have serious mental disorders, and a large percentage of 
those disorders have been shown to be responsive to med-
ication in school-age children (e.g., Lavigne et al., 1996). 
These findings, coupled with the fact that children with 
these disorders have been grossly underdiagnosed and 
undertreated in previous decades, support a reasonable case 
for increasing the use of medication with this age group 
(e.g., Jensen et al., 1999). These controversial issues sur-
rounding the use of Ritalin and other drugs in children have 
led federal policy-makers to make research in this area a 
high priority (e.g., Otto, 2000). 
These studies highlight several important facts regarding 
ADHD and its treatment. 
• ADHD is a significant problem affecting millions of 
children and is associated with a number of potentially 
adverse outcomes. 
• Converging evidence suggests that a well monitored 
pharmacological intervention is a critical component 
for managing the symptoms of ADHD. 
• Psychosocial treatments often should be included in 
the management of comorbid psychiatric and educa-
tional disorders frequently co-existing with ADHD. 
• A number of important issues remain unresolved con-
cerning the use of medications in treating childhood 
behavior problems. 
The purpose of this article is to help provide information 
and guidelines for the effective use of medications in treat-
ing ADHD. Our goals are threefold. 
1. We describe some basic principles of psychopharma-
cology and provide information on the medications 
that have been used to treat ADHD successfully. 
2. We explain current "best practices" for assessing the 
effects of medication for treatment of ADHD. 
3. We discuss some of the limitations of our knowledge 
regarding the effects of medication in children, 
including areas still under study. 
BASIC PRINCIPLES OF 
PSYCHOPHARMACOLOGY 
Psychopharmacology is the study of the psychological 
and behavioral effects of drugs. Teachers and parents who 
are knowledgeable about basic principles of psychopharma-
cology will be able to better understand the manner in which 
medications alleviate behavior problems in the children with 
whom they interact. We will describe four basic concepts: 
1. Clinical effects versus the side effects of medication. 
2. The "dose-response" relation. 
3. Half-life. 
4. Peak effects. 
We then describe the three major classes of medications 
that have been studied for treating ADHD, as well as specific 
3 
drugs from these classes and the research findings and ri ks 
associated with the use of each drug. 
Clinical Effects Versus Side Effects 
When medication is used to treat ADHD, or any other 
behavioral or emotional problem, the goal is to achieve a 
"clinical" effect. That is, the drug should reduce impair-
ment, typically by reducing the behavior/emotional prob-
lems that are causing difficulty in a person's life, and 
thereby provide some relief from suffering. If possible, the 
medication also should promote the individual's adaptive 
effectiveness-school functioning, peer acceptance, family 
functioning, and so on. 
These drugs sometimes are referred to as "psychoactive" 
or "centrally acting drugs." This is because the primary site 
of action for these drugs lies somewhere in the central ner-
vous system (CNS): the brain, the spinal cord, and the 
peripheral nerve . Drugs that act in the CNS have the poten-
tial to influence the functioning of all aspects of mood, 
behavior, and the whole range of psychological proces e , 
including attention, concentration, sensation, perception, 
mood, motivation, appetite, and motor behavior. 
Furthermore, centrally acting drugs usually exert their 
effects in the nervous system by altering the way in which 
certain chemicals, known as neurotransmitters, function. 
Each kind of neurotransmitter usually is associated with 
several different kinds of functioning within the brain. For 
example, one common neurotransmitter known as dopamine 
is associated with motor activity, the ability to inhibit behav-
ior, and motivation and reward. 
Because centrally acting drugs act on neurotransmitter 
systems and these systems may be responsible for more than 
one kind of functioning, their use can result in some effects 
that are not of clinical interest and may even be unpleasant 
or unwanted. For instance, the stimulant drugs used for 
treating ADHD may be effective because they alter the func-
tioning of the neurotransmitters norepinephrine and 
dopamine, which are associated with processes such as 
attention and concentration. The clinical effects of stimulant 
drugs, then, are the result of action in specific neurotran -
mitter systems (for a review of how drugs work on neuro-
transmitter systems, see Wilens, 1999). These neurotrans-
mitters, however, also are associated with elevated arousal 
elsewhere in the central nervous system. Consequently, in 
addition to the clinical effects of improving concentration 
and attention, these drugs may increase blood pressure and 
heart rate, increase respiration, decrease appetite, and dis-
rupt sleep patterns in some individuals. 
Part of the successful management of any behavioral or 
psychological problem through the use of medication is to 
balance the beneficial clinical effects of the medication with 
the potential side effects. The approach for striking a balance 
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is discussed below in addressing best practices for asses·s-
ment of medication effects. To summarize, though, because 
of the way that drugs work in the nervous system, many 
drugs that positively change some aspect of behavior, think-
ing, or emotion might also have other, not-so-positive side 
effects. 
The "Dose-Response" Relation 
A basic principle of pharmacology is that the effects of a 
drug (a "response" of some sort related to behavior change) 
are systematically related to the amount of drug (the "dose") 
in the body. This relation, called the dose-response function, 
can be displayed graphically to show the effects of various 
doses of a drug on some aspect of behavior. One important 
facet of the dose-response function is that the manner in 
which doses influence various areas of functioning (acade-
mic, social, emotional) varies considerably, both across chil-
dren and even within the same child (Douglas, Barr, 
Desilets, & Sherman, 1995; Sprague & Sleator, 1977; Tan-
nock, Schachar, Carr, & Logan, 1989). This basic principle 
of psychopharmacology again underscores the need for indi-
vidualized assessment of drug effects. 
Another important feature of the dose-response relation 
is that it is not always a linear function. It is not true that if 
a small dose of a drug is moderately effective in managing 
some problem behavior, a larger dose always will be better. 
The way in which different children respond to medications 
could result in very different dose-response profiles. The 
response of individual children to varying doses of a drug 
can be categorized in at least four ways (e.g., Rapport, 
DuPaul, Stoner, & Jones, 1986): 
1. Behavioral improvement is related to step-wise in-
creases in dose; 
2. Behavioral improvement is subject to a "threshold" 
effect at a moderate or high dose; 
3. Behavioral improvement reaches a peak at a moder-
ate dose and shows a decrease at higher doses; or 
4. Behavioral improvement is inconsistent across doses. 
These patterns of responding are illustrated in Figure 1, 
which also shows how the dose-response relationship can be 
presented graphically. 
This figure also highlights the necessity of examining 
several different doses of medication to determine conclu-
sively which dose is optimal for managing a specific behav-
ioral problem. For example, if a clinician were to prescribe 
only a relatively high dose of medication to the child in 
Panel C without also evaluating other doses, he or she could 
conclude erroneously that the medication was not effective 
because this specific dose had little effect. Similarly, pre-
scribing only a low dose for this child would not have much 
effect. Only by examining different doses in comparison to 
one another can a physician determine confidently which 
dose is the most effective for managing a behavior problem. 
Half-Life 
r 
Another related pharmacological principle is that drugs 
are broken down and eliminated from the body over a spe-
cific time course and, as this happens, less drug is available 
in the system to influence behavior across the time period. 
Because, as we just described, the effects of a drug are 
related to the amount of drug in the body, it follows that the 
faster the drug is broken down and eliminated from the 
body, the shorter is the amount of time the drug will exert its 
effects. This is exactly the case. 
The rate at which different drugs are broken down and 
eliminated from the body is described generally as the half-
life of a medication. This term is used to describe the time 
required to eliminate half of a drug from the body (hence the 
term half-life). For example, the half-life of normally 
administered methylphenidate (Ritalin) is 2 to 3 hours 
(Julien, 1998). This means that it takes between 2 and 3 
hours for half an initial dose to be eliminated from the body. 
This also means that 4 to 6 hours after taking a dose of 
methylphenidate, only 25% is left in the body-50%, or half 
of the drug, is left after the first 2-3 hours, and 50% of 50% 
(25%) is left after another 2-3 hours. 
The half-life of other drugs can be much longer. For 
example, fluoxetine (Prozac), an antidepressant drug that 
has been used to treat ADHD has a half-life of 1 to 4 days. 
This means that, especially if the medication is administered 
daily, it takes much longer for the drug to be eliminated 
completely from the body. Conversely, it also means that it 
may take several days (or weeks) for a drug to reach "ther-
apeutic levels" in the body. 
For example, suppose that a drug has a half-life of 1 day 
(24 hours) and a dose of 10-mg is prescribed once daily. On 
the second day, 5 mg is left in the body, and this is added to 
that day's additional 10 mg dose. On the third day, 2.5 mg 
of the original dose, plus 5 mg of the second dose, plus 10 
mg of that day's dose is left in the body, for a total of 17.5 
mg. This regimen may be continued until reaching a certain 
level of the drug in the body, at which time the dosing regi-
men may be altered to maintain this level. 
One might ask why not just administer a larger dose all 
at once? In general, this might not be possible with some 
drugs because of potentially problematic side effects of 
large doses given in one administration. In any case, an 
understanding of the concept of half-life of drugs is impor-
tant to help teachers and parents understand the dosing reg-
imen on which their child may be placed. Further, this infor-
mation might be helpful in determining whether changes or 
aberrations in behavior or other functioning of a child are 
likely the result of drug effects or other factors. 
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FIGURE 1 
Different Dose-Response Patterns for Several Different Doses of a Drug. 
The half-life of a given medication typically varies some-
what across individuals. For example, the average half-life 
of methylphenidate (Ritalin) is between 2 and 3 hours. For 
a child in whom Ritalin has a half-life of 2 hours, only 25% 
of the medication would remain 4 hours after a dose. By 
contrast, a child in whom Ritalin has a half-life of 3 hours 
would not eliminate that much of the medication until 6 
hours after a dose. These differences may require different 
dosing regimens for different children to attain maximum 
clinical efficacy. The former child may benefit from doses 
administered every 4 hours, whereas the latter child may 
benefit from a more delayed regimen. Of course, as noted 
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previously, the best way to determine the best dosing sched-
ule is to conduct an individualized medication assessment. 
Peak Effects 
The final basic principle of psychopharmacology that is 
important for parents and teachers to understand is that 
drugs (especially the stimulants; see Table 1) often exert 
their optimal clinical (i.e., behavior-improving) effects at a 
certain point after administration. This time point often is 
referred to as the time of peak effects and, because it is 
related to the concept of half-life, varies across drugs. For 
example, the peak effects for standard formulations of 
Ritalin usually occur 1.5-2 hours after administration. This 
means that, although beneficial effects may be observed 
sooner, the maximal effect of the drug is not likely to occur 
until later and the effects after that time may begin to 
diminish. 
Sometimes the way a drug is administered influences the 
peak effects. For example, Ritalin is availabl~ in sustai~ed 
release formulations that may influence the time at which 
peak effects are observed and the length of time the drug 
remains clinically active (Birmaher, Greenhill, Cooper, 
Fried, & Maminski, 1989; Pelham, Sturges, et al., 1987). 
Understanding when different drugs exert their peak 
effects can provide valuable information to parents and 
teachers who are administering or overseeing use of the 
drug. For example, a child whose attentional and concen~ra-
tion deficits are particularly problematic in math class, Just 
before lunch, might not benefit from a dose of standard 
Ritalin administered 4 or 5 hours earlier at breakfast, as the 
peak effects of the medication likely will occur 1.5 to 2 
hours after administration. 
An important caveat to the above principles of psy-
chopharmacology is that the patterns of side effects, dos~-
response functions, half-life, and peak effects are no~ u_m-
form across individuals. In fact, considerable vanat10n 
exists in these concepts, even within the same individual. 
For example, as noted previously, the specific behavior 
under study influences the relation between the amount of 
drug and the extent of behavior change (the dose-response 
relation). Similarly, factors such as presence of other pre-
scription or over-the-counter medications, recent meals, or 
sleep patterns might all influence the half-life or peak 
effects, or both, of drugs within the same child. 
These characteristics of drug effects underscore two 
important facts that will be discussed below. 
1. The only way to confidently determine the specific 
effects of a drug for any given child is to conduct a 
carefully controlled drug assessment. 
2. Generally speaking, drugs affect individuals in dif-
ferent ways. 
This principle of psychopharmacology is important, as it 
can influence the expectations of important individuals who 
interact with a medicated child, such as parents and teach-
ers. For example, a teacher who observed one child in his or 
her class respond well following a treatment regimen with 
Ritalin might not see the same positive effects in another 
child prescribed the same medication. 
Drugs used to treat ADHD 
The drugs used most frequently to treat ADHD in chil-
dren and adolescents fall into three general categories: stim-
ulants, antidepressants, and antihypertensive agents. We will 
discuss each of these next, including a description of the 
drug class, identification of specific drugs shown to be 
effective for ADHD, recommended doses, contraindications 
for use, and common side effects. 
Stimulant Drugs. 
In general, stimulant drugs have an effect on the central 
nervous system that can be seen by things such as increased 
heart rate and blood pressure, increases in activity and alert-
ness, and increases in thinking processes. By far, the stimu-
lants are used more than any other class of drug to treat 
ADHD. Roughly 80% of school-aged children (5-14 years 
of age) with ADHD who are treated with medication receive 
some kind of stimulant drug (Zito et al., 1999). Other stud-
ies have documented the growing use of stimulant medica-
tions in preschool children ( 1-5 years of age) diagnosed 
with ADHD or presenting similar kinds of problems (Rapp-
ley et al., 1999; Zito et al., 2000). Probably as a result of 
their widespread use, stimulants also have been researched 
most widely in children diagnosed with ADHD. 
A MEDLINE database search using the key terms 
"ADHD" and "stimulants" produced nearly 300 research 
studies. We will review briefly the four stimulant drugs most 
commonly prescribed including general clinical benefits, 
psychopharmacological properties, contraindications (situa-
tions in which use of the medication is not advisable), and 
side effects. This information is also summarized in Table 1. 
I. Methylphenidate (Ritalin). Methylphenidate is the 
generic or chemical name for the drug Ritalin. It is the most 
commonly prescribed stimulant for ADHD and has been 
demonstrated to be effective for a wide range of problem 
behaviors. Some of the behavioral, emotional, and academic 
areas in which Ritalin has demonstrated beneficial effects 
include: academic productivity and accuracy (e.g., Elia, 
Welsh, Gulotta, & Rapoport, 1993); parent and teacher 
behavior ratings (e.g., Barkley et al., 1991); aggression and 
other antisocial behavior (e.g., Bukstein & Kolko, 1998); 
and social functioning and peer relations (e.g., Barkley & 
Cunningham, 1979). 
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TABLE 1 
The Stimulants: Drugs, Clinical Effects, Contraindications, Dosing Information, 
Peak Effects, Half-life, and Side Effects 
Drug ,feature Methylphenidate d-amQhetamin Amphetamine Salts 
Brand Name Ritalin Dexedrine Cylert Adderall 
Areas Shown to Short-term academic Short-term academic Short-term academic Short-term academic 
be improved performance, teacher performance, teacher performance, teacher performance, teacher and 
and parent behavior and parent behavior behavior ratings, parent ratings, on-task 
ratings, aggression, ratings on-task behavior behavior 
social functioning 
Contraindications Tics, Tourette's Hypertension, Hepatic (liver) Hypertension, 
to Use disorder, glaucoma, hyperthyroidism, problems, psychosis hyperthyroidism, 
marked anxiety or cardiovascular cardiovascular disease 
agitation, psychosis disease, tics, 
Tourette's disorder 
Recommended 5-10 mg twice a day/ 2.5-5 mg one or 37 .5 mg once daily/ 2.5-5 mg once or twice 
Starting/ 60 mg daily two times daily/ 112.5 mg daily/60 mg daily 
Maximum Dose 40 mg daily 
Duration of 3-4 hours/1-2 hours 4 hours/2-3 hours Up to 6 hours/ Dose dependent, 3.5-6.4 
Action/Peak dose-dependent, hours/dose dependent 
Effects 2-6 hours 1.5-3.0 hours 
Half-life 2-3 hours 6-7 hours 2-12 hours Not determined; probably 
similar to d-amphetamine 
Common Insomnia, decreased Insomnia, decreased None substantially Insomnia, decreased 
Side Effects appetite, appetite, irritability, different from placebo appetite, but not 
stomachaches, anxiousness, crying, significantly different from 
headaches, dizziness sadness/unhappiness, placebo at group level 
nightmares 
According to the Physician's Desk Reference (PDR; 
2000) the typical dose of Ritalin for children begins at 5 mg 
twice daily (before breakfast and before lunch) and is 
adjusted upward to maximize efficacy. It is recommended 
that children not take more than 60 mg per/day, although 
physicians will help determine the optimal dose for each 
child. The effects of Ritalin are not related to the child's 
weight (Rapport, DuPaul, et al., 1986). Heavier children do 
not necessarily require higher doses of Ritalin than lighter 
children to achieve he same clinical effects. The PDR also 
recommends that Ritalin not be prescribed to children 
younger than 6 years of age, although this practice seems to 
be widespread (e.g., Zito et al., 2000). Some controversy 
surrounds the clinical efficacy or extent of side effects 
reported in young children who are prescribed Ritalin. The 
National Institutes of Health (NIH) currently is funding 
research to determine whether Ritalin is effective and safe 
for preschool children. 
Ritalin exerts its peak effects 1-2 hours after administra-
tion and has a half-life of 2-3 hours (Julien, 1998). The 
duration of action of Ritalin, or the length of time its bene-
ficial clinical effects can be observed, is approximately 3-4 
hours at regular doses (Julien, 1998). Ritalin is available in 
a sustained-release formulation that produces more variable 
peak effects and half-life of the drug (Birmaher et al., 1989). 
Nevertheless, for some children, this formulation of drug 
may be preferable, and it has been shown to be effective in 
reducing problems associated with ADHD (e.g., Pelham, 
Sturges, et al., 1987; Pelham, Greenslade, et al., 1990). In 
June of 2000 the Alza Pharmaceutical Company received 
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FDA approval for a different delivery device that should 
help reduce the number of doses children require each day 
and provide more sustained blood levels across the day. 
Known as OROS and marketed under the name Concerta, 
this small capsule contains a quantity of liquid Ritalin in a 
lower chamber. The upper chamber is empty when swal-
lowed. As water is absorbed from the gastrointestinal tract 
into the upper chamber, however, it exerts a continuous 
pressure on the lower chamber, squeezing out an even 
amount of drug across the school day. It thereby provides for 
more even blood levels and hence more continuous treat-
ment of ADHD symptoms over a longer time than standard 
Ritalin. 
Caution is recommended in the use of Ritalin if the child 
has a history of tics or a history of Tourette's disorder (TD), 
if the child is excessively agitated or anxious, or if the child 
is psychotic. In these cases, closer monitoring of the child's 
drug response and lower initial starting doses might be nec-
essary until the child's response can be determined more 
fully. Some children with these conditions can take stimu-
lants without experiencing significant difficulties, whereas 
others may be at risk for adverse responses, such as worsen-
ing of their tics, anxiety, or thought disorder. 
The side effects of Ritalin reported most commonly in 
children with ADHD are insomnia, decreased appetite, 
stomachache, headache, and dizziness. In a large sample of 
children with ADHD, all of these side effects were found to 
occur more frequently than in a placebo condition (in which 
children received a capsule with no medicine in it) and were 
reported with relatively equal frequency at low (0.3 mg/kg) 
and higher (0.5 mg/kg) doses (Ahmann et al., 1993). 
2. Dextroamphetamine (Dexedrine). Dextroamphetamine, 
the generic name for the drug Dexedrine, also has been 
shown to be effective for a range of behavior problems asso-
ciated with ADHD. Although equally effective as Ritalin for 
a number of behavior problems associated with ADHD, 
Dexdrine is not prescribed as frequently. This is likely 
because of the greater potency and longer duration of action 
of the drug relative to Ritalin, which may lead to more pro-
nounced side effects with Dexedrine. As noted, Dexedrine 
has been shown to improve school performance (e.g., Elia et 
al., 1993) and teacher and parent ratings of behavior prob-
lems (e.g., Gillberg et al., 1997). 
According to the PDR, the recommended starting dose 
for Dexedrine is 2.5-5 mg once or twice daily before break-
fast, and possibly before lunch. A physician then should 
titrate the dose upward to achieve maximum clinical effects. 
It is recommended that children not be prescribed more than 
40 mg daily. According to the guidelines in the PDR, 
Dexedrine can be used with younger children than Ritalin 
can (as young as 3 years of age). The peak effects come 
approximately 2-3 hours after administration, and the drug 
has a half-life of approximately 6-7 hours (Julien, 1998). 
This means that the peak effects typically are seen after the 
peak effects for Ritalin are seen. Like Ritalin, Dexedrine is 
available in a sustained-release formulation, thereby extend-
ing the time course of its clinical effects (e.g., Pelham et al., 
1990). 
Dexedrine is contraindicated, or at least should be used 
more cautiously, if the child experiences tics or has a history 
of Tourette's disorder, hypertension, hyperthyroidism, glau-
coma, or cardiovascular abnormalities. Given the similarity 
between Dexedrine and Ritalin, it should not be surprising 
that the side effects are similar, although they usually are 
more pronounced with Dexedrine at the same dose. It has 
been shown to significantly increase insomnia and appetite 
suppression and, compared to Ritalin, has been shown to 
produce significantly higher levels of insomnia, irritability, 
crying, anxiousness, sadness/unhappiness, and nightmares 
(Efron, Jarman, & Barker, 1997). 
3. Pemoline (Cylert). Pemoline is the generic name for 
the drug Cylert. The drug typically is used either when chil-
dren do not respond to other stimulants or when multiple 
daily dosing is not possible or is impractical. Cylert is 
administered only once daily, in the morning. It is generally 
not considered a "frontline" treatment for ADHD because of 
its potentially severe side effects. Cylert has been shown to 
be effective in improving academic performance, on-task 
behavior, and teacher ratings (e.g., Conners & Taylor, 1980; 
Pelham, Swanson, Furman, & Schwindt, 1995). 
The PDR and package information for Cylert recom-
mend a starting dose of 37 .5 mg administered once daily and 
a maximum dose of 112.5 mg. Although there is some dis-
agreement as to how long after initiation of drug treatment 
that clinical effects are observed, well controlled studies 
have demonstrated that these effects occur within 2 days of 
drug administration (e.g., Connors & Taylor, 1980; Pelham, 
Greenslade, et al., 1990; Pelham, Swanson, et al., 1995). 
Peak effects for Cylert seem to depend on dose, with the 
highest doses evaluated (112.5 mg; Pelham, Swanson, et al., 
1995), demonstrating peak effects 6 hours after administra-
tion, whereas lower doses reached peak effects 2-4 hours 
after administration. The half-life for Cylert is 2-12 hours 
(Julien, 1998) and one controlled study of children with 
ADHD reported a half-life of 8.6 hours (Sallee, Stiller, & 
Perel, 1992). 
The most salient side effect of Cylert is its association 
with potentially fatal liver failure. Although this side effect 
is infrequent and reversible if detected early enough, the 
risks and associated monitoring necessary for safe use of the 
drug probably limit the frequency of its use (Julien, 1998). 
The manufacturer recommends that this drug be a last resort 
for managing children with ADHD, and at some point, it is 
likely to be discontinued from commercial production. Not 
surprisingly, the use of Cylert is contraindicated in children 
who have a history of liver problems. Other side effects 
reported with the use of Cylert are minimal and do not seem 
to differ substantially from those reported with the placebo 
(Pelham, Swanson, et al., 1995). 
4. Mixed Amphetamine Salts (Adderall). Adderall is the 
trade name for a generic compound of mixed amphetamine 
salts (three forms of d-amphetamine and one of I-ampheta-
mine ). It has become available for use with ADHD rela-
tively recently compared to the other stimulants. Adderall 
has been shown to be equally as effective as Ritalin in 
reducing problem behavior in a classroom setting, improv-
ing parent and teacher behavior ratings, and improving aca-
demic performance (Pelham, Aranoff, 1999; Swanson et al., 
1998a). 
The recommended starting dose for Adderall is 2.5 mg 
once or twice daily for children between 3 and 6 years of 
age, and 5 mg once or twice daily for children aged 6 and 
older. It is recommended that the maximum daily dose not 
exceed 40 mg (PDR). As noted previously, Adderall has 
generally been shown to be as effective as Ritalin in reduc-
ing symptoms of ADHD (e.g., Pelham, Aronoff, et al., 1999) 
and has been shown to be somewhat more potent (i.e., lower 
doses of Adderall yield effects similar to higher doses of 
Ritalin). For example, Pelham, Aronoff, et al. (1999) 
demonstrated that twice daily dosing of 12.5 mg Adderall 
resulted in greater effect sizes across dependent variables 
than either 10 mg or 17 .5 mg of Ritalin administered twice 
daily. 
Swanson et al. (1998a) reported that the duration of 
behavioral effects of Adderall was generally dose-depen-
dent, with higher doses resulting in longer duration of action 
(e.g., 5 mg = 3.52 hours; 20 mg = 6.40 hours). This same 
study found similar results for the time of peak effects for 
Adderall, with lower doses resulting in shorter times to peak 
effects (e.g., 5 mg= 1.5 hours; 20 mg= 3.0 hours). In gen-
eral, both the duration of action and the time to peak effects 
is longer for Adderall than Ritalin (Swanson et al., 1998a). 
The half-life of Adderall has not been determined conclu-
sively, but, given its chemical composition, would be 
expected to be similar to that for Dexedrine ( e.g., 6-7 
hours). 
Because Adderall is composed primarily of amphetamine 
salts, the contraindications are similar to those for Dexedrine: 
a history of hypertension, hyperthyroidism, or cardiovascu-
lar problems. Based on the few existing clinical studies of 
Adderall, its side effects are minimal. Side effects reported 
by more than 10% of the samples studied on any dose of 
Adderall include: insomnia, loss of appetite, sadness/ 
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unhappiness, proneness to crying, and picking at the skin or 
fingers (Manos, Short, & Findling, 1999; Pelham, Aronoff, 
et al., 1999; Swan on, Wigal, et al., 1998a). In general, how-
ever, these side effects did not occur significantly more fre-
quently under Adderall conditions than conditions in which 
children received a placebo, suggesting that the side effects 
the drug itself produces are minimal. 
Antidepressant Drugs 
Keeping in mind that the majority of children (80% or 
more) treated with medication for ADHD receive one of the 
stimulants listed above, we now will review some other 
drugs that have been shown to be useful in managing symp-
toms associated with ADHD. In their recent survey of pre-
scription drug practices for children with ADHD, Zito et al. 
(1999) reported that 17.2% of all children with ADHD 
treated with medication received a pharmacological agent 
other than a stimulant. Typically, antidepressants or antihy-
pertensive agents are used either when children do not 
respond to stimulant treatment or when co-occurring psy-
chological, emotional, or behavioral problems are present. 
As their name implies, the antidepressants are used in the 
frontline treatment of depressive disorders. Because of the 
specific neurotransmitters on which they work in the ner-
vous system, however, they also are helpful in treating 
ADHD. Several different sub-classes of antidepressants 
have been used to treat symptoms of ADHD. These sub-
classes and some of the specific drugs in each subclass are 
discussed below and are summarized in Table 2. 
1. Tricyclic antidepressants (desimpramine, imipramine). 
The subclass of tricyclic antidepressant drugs has been eval-
uated extensively ince at least the 1960s for treatment of 
childhood behavior problems (Popper, 1997). The represen-
tative tricyclic antidepressants included here are generic 
names and also are identified by their trade names Nor-
pramin (desipramine) and Tofranil (imipramine). In general, 
the tricyclics have been shown to improve clinician, parent, 
and teacher ratings of behavior in children who receive this 
medication (e.g., Biederman, Baldessarinini, Wright, Knee, 
& Harmatz, 1989). 
Some concern has been raised, however, as to whether 
the effects of these medications on cognition or attention are 
as substantial as the effects seen with stimulants (Popper, 
1997). For example, one study demonstrated that imipramine 
did not produce changes in perceptual-motor performance 
tasks beyond those seen with a placebo, whereas Ritalin sig-
nificantly improved performance (e.g., Spring, Yellin, & 
Greenberg, 1976). 
Recommended doses for the tricyclics in the treatment of 
ADHD are somewhat difficult to ascertain because these 
drugs have not been developed or marketed specifically for 
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TABLE 2 
The Antidepressant: Drugs, Clinical Effects, Contraindications, Dosing Information, 
Peak Effects, Half-life, and Side Effects 
Representative Drugs 
(Generic name/ 
Brand name) 
Areas Shown to be 
improved 
Contraindications 
to Use 
Recommended 
Starting/Maximum 
Dose 
Duration of Action/ 
Peak Effects 
Half-Life 
Common Side Effects 
lmipramine/Tofranil (IMI) 
Desipramine/Norpramin (DMI) 
Parent, teacher, clinician ratings 
Concurrent use of Monoamine 
Oxidase Inhibitors (MAOls) 
IMI: 25 mg once daily/ 
75 mg daily 
DMI: 25-100 mg once daily/ 
150 mg* 
Unknown 
IMI: 10-20 hours 
DMI: 12-75 hours 
AMY: 20-35 hours 
Cardiac changes (arrhythmia, 
blood pressure changes) 
Blurred vision, dry mouth, 
constipation** 
Fluoxetine/Prozac (FLU) 
Sertraline/Zoloft (SER) 
Venlafaxine/Effexor (VEN) 
Clinician, teacher ratings, 
laboratory measures of 
impulsivity, IQ 
Concurrent use of 
Monoamine Oxidase 
Inhibitors (MAOls) 
PRO: 27 mg/day* 
SER: 25 mg 
VEN: 60mg/day* 
Unknown 
FLU: 24-96 hours 
SER: 26 hours 
VEN: 3-11 hours 
Nausea, insomnia, diarrhea** 
Increases in hyperactivity 
Bupropion/Wellbutrin 
Parent, teacher, clinician 
behavior ratings, cognitive 
performance, laboratory 
measures of impulsivity 
Concurrent use of 
Monoamine Oxidase 
Inhibitors (MAOls), seizure 
disorder, bulimia, or anorexia 
nervosa 
1-3 mg/kg twice daily 
(35-100 mg)/ 
250-300 mg daily 
Effects noted within 2 weeks 
for some variables 
8-14 hours 
Drowsiness, nausea, 
skin problems 
* Recommended doses from PDR for other problems. Doses not established for use with children with ADHD. 
** Side effects not shown to occur significantly more frequently than placebo and not established in controlled studies with 
children with ADHD 
use with this population. As such, recommendations estab-
lished for their use with depression may not be the same as 
the doses found in clinical trials to be effective for ADHD. 
For example, the PDR recommends that the maximum daily 
dose of desipramine for adolescents not exceed 150 mg. In 
one controlled study of children and adolescents with 
ADHD, however, desipramine exerted beneficial effects at 
an average dose of 4.6 mg/kg/day, which translates to a daily 
dose of 161 mg for a 35 kg adolescent (Biederman et al., 
1989). Table 2 gives the initial and maximum doses listed in 
the PDR for each of these drugs. Where possible, the dose 
levels recommended for children or adolescents are 
included. 
Tricyclics (and antidepressants in general) have a much 
longer half-life than the stimulants do. As such, they are 
considered to be longer acting, although beneficial effects 
often are not seen for several days following initiation of 
their use (e.g., Popper, 1997). Given the long and relatively 
wide-ranging half-life of these drugs, it is somewhat diffi-
cult to determine the duration of action and peak effect times 
as precisely for these medications. Table 2 gives the values 
derived from several clinical studies with children with 
ADHD. 
The primary contraindication to the use of the tricyclics 
(as well as the serotonin reuptake inhibitors and the atypical 
antidepressant Wellbutrin) is the concurrent use of another 
kind of antidepressant medication called monoamine oxi-
dase inhibitors (MAOis). Side effects of the tricyclic antide-
pressant medications can be substantial and are likely 
another reason why their use with children is limited. Com-
mon side effects reported in children include constipation, 
drowsiness, and increases in blood pressure (Rapoport, 
Quinn, Bradbard, Riddle, & Brooks, 1974). 
Tricyclics also can have potentially serious effects on car-
diac (heart) functioning (e.g., Greenberg & Yellin, 1975), and 
some have suggested that the risks of arrhythmias and other 
heart problems associated with some tricyclics (such as 
desipramine) are significant enough to warrant extreme cau-
tion. In fact, there have been several reports of sudden death 
in children who have taken these medications (e.g., Varley & 
McClellan, 1997), although others have suggested that these 
reports are inconclusive with respect to their safety with chil-
dren (e.g., Wilens et al., 1996). Many physicians recommend 
that the child receive an electrocardiogram (ECG) prior to 
the use of tricyclics, as well as when doses are changed. 
Other side effects common with this class of medication 
include blurred vision and dry mouth, the extent of these side 
effects in children treated for ADHD is unclear. 
2. Selective serotonin-reuptake inhibitors (SSR/s). The 
SSRI class of antidepressants is named for the action they 
exert on the central nervous system and includes drugs such 
as fluoxetine (Prozac), sertraline (Zoloft), and venlafaxine' 
(Effexor). In one early study of the effects of Prozac, teacher 
and clinician ratings were shown to be improved after 6 
weeks of treatment (Barrickman, Noyes, Kuperman, Schu-
macher, & Verda, 1991). Other, more recent studies, how-
ever, have been less conclusive. For example, one study 
demonstrated that in children with both ADHD and depres-
sion, neither Prozac nor Zoloft was effective in reducing 
attentional problems, although both drugs were effective in 
alleviating depressive symptoms (Findling, 1996). 
Another study reported that less than half of a group of 
16 children with ADHD showed improvement or tolerated 
side effects when treated with Effexor (Olvera, Pliszka, Luh, 
& Tatum, 1996). This is in spite of the fact that this medica-
tion has been shown to be effective for adults with ADHD 
1 Because it act both to block the reuptake of serotonin and acts on the 
neurotransmitter noradrenaline, venlafaxine sometimes is considered an 
"atypical" antidepressant (Wilens, 1999). For purposes of organization, 
we will classify it with the other SSRTs. 
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(e.g., Adler, Resnick, Kunz, & Devinsky, 1995), although 
these studies also reported high proportions of patients who 
did not tolerate side effects. 
Overall, the SSRis have been shown to be somewhat 
effective in managing ADHD in children and adolescents. 
The lack of well controlled studies, however, and the high 
rates of side effects and nonresponders, call into question 
the overall utility of these drugs as a primary therapy for 
ADHD. 
As was the case with tricyclic antidepressants, identify-
ing a specific recommended dose of SSRis for children is 
difficult, as their use has not been studied widely in children 
with ADHD. The PDR does not explicitly recommend dose 
levels for use with children or adolescent for either Prozac 
or Effexor, although studies reporting their use with children 
with ADHD used doses that averaged 27 mg/day (-0.6 
mg/kg/day) for Prozac (Barrickman, Noyes, et al., 1991) 
and 60 mg/day (-1.4 mg/kg/day) for Effexor (Olvera et al., 
1996). The PDR does provide guidelines for doses of Zoloft 
with children and adolescents, as the drug has been used in 
young patients with obsessive-compulsive. problems. 
The recommended starting dose is 25-50 mg, and the 
maximum daily do e is 200 mg. One study of Zoloft use 
with ADHD and depre sion began with 25 mg but failed to 
show significant improvement in attentional symptoms 
(Findling, 1996). The half-lives of the SSRis are generally 
longer than even the tricyclic antidepressants, and they vary 
considerably: 24-96 hours for Prozac, 26 hours for Zoloft, 
and 3-11 hours for Effexor (Julien, 1998). Ascertaining how 
quickly this class of drugs exerts effects on ADHD i diffi-
cult because the tudies that have been conducted have not 
reported ongoing re ults but rather, how patients were func-
tioning at the beginning of treatment and after several 
weeks. Although these drugs usually are expected to take 
days or weeks to begin to show effects for depressive prob-
lems, more careful investigation is warranted before conclu-
sions can be drawn about the time course of action with 
ADHD symptoms. 
In the few published studies of SSRis and ADHD, the 
side effects have been relatively minor. One study using 
Effexor reported that 3 of 16 participants in the sample dis-
continued the study because of increases in hyperactivity, 
and one other subject discontinued because of severe nausea 
(Olvera et al., 1996). Another study using Prozac reported 
that 6 of 19 subjects complained of side effects such as 
facial rash and feeling "spacey," but that these effects did 
not lead to dropping out of participation in the study (Bar-
rickman et al., 1991 ). 
3. Other antidepressants. One other antidepressant med-
ication that has been used for treating ADHD warrants dis-
cussion and is pharmacologically unrelated to tricyclics and 
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SSRis. Bupropion, the generic name for the drug Weli-
butrin2, has been shown in several controlled trials (e.g., 
Barrickman et al., 1995; Conners et al., 1996) to improve 
parent, teacher, and clinician ratings of behavior. These 
studies also showed Wellbutrin to be effective in improving 
the performance of children with ADHD on measures of 
attention, vigilance, and impulsivity. Moreover, it has been 
shown to be effective in treating youth with ADHD who also 
have concurrent conduct problems such as aggression and 
substance use/abuse (Riggs, Leon, Mikulich, & Pottle, 
1998). 
The doses used to treat children and adolescents with 
ADHD have ranged from 1.4-6.0 mg/kg/day (maximum 
daily dose 250 mg) (Barrickman, Perry, et al., 1995; Con-
ners et al., 1996). The study examining ADHD adolescents 
with concurrent problems with drug use and conduct prob-
lems found a maximum daily dose of 300 mg to be effective 
(Riggs et al., 1998). Beneficial effects of Wellbutrin have 
been observed as soon as 3 days after drug treatment began 
(Conners et al., 1996), and clinical improvements have been 
maintained after continued administration for up to 6 weeks 
(Barrickman, Perry, et al., 1995). 
In addition to its contraindication with the concurrent use 
of MAOis, Wellbutrin should not be used if a child or ado-
lescent has problems with bulimia or anorexia nervosa or 
has a history of seizure problems, as the drug may compli-
cate these problems. Wellbutrin has a relatively benign pro-
file of side effects. Skin problems, drowsiness, and nausea 
have all been reported as adverse side effects in Wellbutrin 
studies with children having ADHD, although these reac-
tions typically were not more frequent than those reported 
by individuals receiving capsules containing no active med-
ication (Barrickman, Perry, et al., 1995; Conners et al., 
1996). 
Antihypertensive Drugs 
At least two drugs that are used primarily for managing 
high blood pressure have been shown to be effective in some 
cases in the management of ADHD in children. We briefly 
review the profile of clinical and side effects for two of these 
drugs for which controlled clinical studies exist. A summary 
of these findings is presented in Table 3. 
1. Clonidine (Catapres). Clonidine is the generic name 
for the drug Catapres, which is used to lower blood pressure 
in adults. Its use for managing ADHD in children and ado-
lescents has increased, and one review reported 39 pub-
lished studies of the use of clonidine in ADHD (Connor, 
Fletcher, & Swanson, 1999). In these studies, clonidine at 
2Bupropion also is marketed under the brand name Zyban as a smoking-
cessation drug. 
doses between 0.1 and 0.24 mg/day has been shown, on 
average, to be effective in reducing clinician, parent, and 
teacher ratings of problematic behavior in a manner compa-
rable to that of the tricyclic antidepressants (Connor et al., 
1999). The time course of action for clonidine in children 
diagnosed with ADHD remains unclear, although, according 
to the PDR, the drug has effects on blood pressure within an 
hour after administration and reaches its peak effects 2 to 4 
hours after administration. 
Side effects of clonidine that were commonly reported in 
the Connor et al. (1999) review included sedation and irri-
tability. Not surprisingly, several of the studies also reported 
cardiac changes, including drops in blood pressure and heart 
rate (Connor, Barkley, & Davis, 2000). Because of the 
potential for changes in cardiac functioning as a result of 
clonidine use, it has been recommended that children receiv-
ing the drug undergo ECG monitoring (Cantwell, Swanson, 
& Connor, 1997). Only three studies reviewed by Connor et 
al. (1999) reported ECG monitoring, and of these, none 
reported clinically significant ECG abnormalities. 
2. Guanfacine (Tenex). Guanfacine is the generic name 
for the antihypertensive drug Tenex. It has been shown to be 
effective in reducing parent-rated behavior problems associ-
ated with ADHD at doses beginning at 0.5 mg/day and 
increasing to an average dose of 3.2 mg/day, given in 3-4 
divided doses throughout the day (Hunt, Arnsten, & Asbell, 
1995). Guanfacine did not result in significant side effects in 
children with ADHD, although some sedation and drowsi-
ness were reported for a small proportion of the sample and 
about 25% of the children in this study reported headaches 
and stomachaches during the early part of the one-month 
trial (Hunt et al., 1995). 
Decision-Making in Selecting a Medication 
Considering the number of drugs that have been used to 
treat ADHD with some effectiveness, a reasonable question 
is how physicians go about making decisions regarding 
medication for ADHD. Many factors influence the decisions 
of individual physicians. Based on clinical experience and 
reviews of the research, the following steps are recom-
mended for making choices regarding medication. 
Barring any contraindications, the first choice of medica-
tion usually should be Ritalin because of its greater docu-
mentation in research, proven efficacy across a wide age 
range, more dose-response information, and wider margin 
of safety than the other two classes of medications reviewed 
here (antidepressants and antihypertensives). 
Because a child's failure to respond to one stimulant, 
such as Ritalin, does not mean that he or she might not ben-
efit from another stimulant (Elia & Rapoport, 1991), a trial 
of Adderrall is recommended as the next step. This drug has 
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TABLE 3 
The Antihypertensives: Drugs, Clinical Effects, Contraindications, Dosing information, Peak Effects, Half-
life, and Side Effects 
Brand Name 
Areas Shown to be 
Improved 
Contraindications to Use 
Recommended Starting/ 
Maximum Dose 
Duration of Action/ 
Peak Effects 
Half-Life 
Catapres 
Parent, teacher, clinician ratings 
None reported 
0.1-0.24 mg/day 
Unknown 
17-41 hours 
Guanfacine 
Tenex 
Parent ratings 
None reported 
0.5 mg/day 
4 mg/day in 0.5 mg increments 
Unknown 
Common Side Effects Sedation, irritability, blood pressure/ 
heart rate changes 
13-14 hours in younger individuals 
Decreased appetite, headaches, 
stomachaches 
been shown to be just as effective as Ritalin and may not 
have as many side effects as Dexedrine (e.g., Swanson et al., 
1998a). 
If Adderall is unsuccessful, a trial of Dexedrine could be 
considered, with the understanding that its potency is higher 
than both Adderall and Ritalin-that is, a lower dose is 
required to influence behavior change and cause side 
effects. If these medications are not effective, a trial of 
Cylert could be considered. The risk of hepatic toxicity of 
this medication, however, requires closer monitoring and 
periodic assessment of liver functioning, making it a less 
benign medication than the other stimulants. 
If none of the stimulant medications are effective, a tri-
cyclic antidepressant (e.g., desipramine or imipramine), 
SSRI (Prozac), or some other antidepressant (Wellbutrin) 
should be considered. Finally, some clinicians elect for a 
trial of one of the antihypertensive agents (e.g., clonidine or 
guanfacine). If these, too, fail, pharmacotherapy may have 
to be discontinued for at least one year, if not altogether 
eliminated from consideration. 
Children younger than 6 years of age who have a poor 
response to stimulants might respond positively in later years 
(after the age of 6). Perhaps more important than the selection 
of specific medication(s)-a decision that is likely influenced 
by many factors-is that the evaluation of whether the drug is 
effective take place in a systematic and structured fashion. 
Best Practices for the Assessment of Drug Effects 
In Children Diagnosed with ADHD 
Once parents and teachers of children with ADHD estab-
lish a basic understanding of psychopharmacology and 
knowledge of the kinds of drugs typically used to treat 
ADHD, they should be made aware of well established pro-
cedures for effectively evaluating the efficacy of medica-
tion. These procedures and recommended guidelines will be 
discussed next. 
Ensuring Proper Assessment and Diagnosis. 
The first step in properly managing behavioral problems 
through medication is to make sure that the child has had an 
adequate physical and psychological examination. Guide-
lines for the proper assessment of ADHD include clinical 
interviews with parents and children, completion of stan-
dardized behavior rating scales by parents and teachers, 
direct observation, and physical examination (Dulcan & 
Benson, 1997). Doctors, parents, and teachers involved with 
assessing ADHD should be prepared to commit the time 
necessary to complete the various components of this 
assessment. A proper assessment must include information 
from several different settings (home, school, etc.) and 
should be conducted by a professional trained explicitly in 
the diagnosis of ADHD. 
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Although clinicians vary with respect to the specific 
instruments used to assess ADHD, we recommend the fol-
lowing, all of which are available in parent and teacher for-
mats and are among the more widely used and well stan-
dardized: Child Behavior Checklist/Teacher Report Form 
(Achenbach & Edelbrock, 1993); Behavioral Assessment 
System for Children (Reynolds & Kamphaus, 1994), 
ADHD-IV Rating Scale (DuPaul, Power, Anastopoulos, & 
Reid, 1999), Disruptive Behavior Rating Scale (Barkley & 
Murphy, 1998); and Revised Conners Rating Scales (Con-
ners, 1997). In addition, semistructured clinical interviews, 
such as the Parental Interview Form (Barkley & Murphy, 
1998), are useful for gathering detailed information regard-
ing the child's behavioral problems. It is important to note, 
however, that, given the overlap between symptoms of 
ADHD and other kinds of behavioral and emotional prob-
lems, assessment and diagnosis of this disorder rarely are 
straightforward and cannot be conducted using rating scales 
alone. 
Although, again, individual clinicians vary as to the 
extent of medical evaluation necessary for each individual 
patient, the following are general recommendations for 
things that should be included in an initial work-up. Some 
components of the initial medical evaluation may be differ-
ent, depending on the type of medication to be selected. 
First, height and weight always should be recorded, and, 
if possible, earlier measurements obtained so the child's 
position and former trajectory on a growth velocity curve 
can be estimated. This makes it easier to evaluate any sub-
sequent change in growth rate, which is especially important 
if stimulant drugs are to be used. 
Possible cardiological abnormalities should be evaluated, 
and blood pressure and pulse taken. Monitoring of cardiac 
functioning is especially important if the child is to be pre-
scribed antidepressant medication. The child's previous eat-
ing and sleeping patterns have to be established, as these are 
areas in which side effects are likely to arise with many of 
the medications. 
Ideally, pretreatment levels of potential behavioral side 
effects should be obtained by administering the Side Effects 
Rating Scale (Barkley & Murphy, 1998) at this time, as 
many clinic-referred children show behavioral/emotional 
problems before beginning medication. Without monitoring, 
these preexisting conditions could easily be confused as side 
effects during the subsequent trial. 
Finally, a careful history should be taken for evidence of 
possible seizure disorders and tics, with follow-up investi-
gation if indicated. Other laboratory tests (CBC, liver func-
tion tests) are needed only as baseline data or as part of a 
routine physical evaluation. They have no routine specific 
application in preparation for prescribing the medications 
discussed in this article, unless Cylert is to be used. 
Issues in the Decision to Use Medication 
Even after a conclusive diagnosis has been established 
and a thorough medical evaluation completed, the deci sion 
to use medication with children who have ADHD should not 
be made without considerable forethought. Parents and 
teachers should keep in mind that, although medication has 
been shown to be most effective in managing these prob-
lems, considerable improvements can be achieved through 
properly implemented psychological/psychosocial interven-
tions (e.g., MTA Cooperative Group, 1999). 
The following rules/questions might be useful in helping 
parents and teachers make informed decisions about the use 
of medication for behavior problems with children who 
have ADHD. These are intended only as rules of thumb, and 
all parties involved clearly should remain flexible regarding 
the unique needs and circumstances of each case. 
1. How old is the child? Pharmacotherapy may be less 
effective or lead to more severe side effects in chil-
dren below 4 years of age (e.g., Firestone, Musten, 
Pisterman, Mercer, & Bennett, 1998) and therefore is 
not usually recommended. Generally, however, little 
is known about the safety and efficacy of medication 
for ADHD in this age range. Research currently is 
being conducted to address this lack of information. 
2. Have other therapies been used? If this is the fam-
ily's initial contact with the professional, prescrip-
tion of medication might be postponed until other 
interventions (e.g., parent training in child manage-
ment skills or psychosocial treatment for the child) 
have been attempted because, under some circum-
stances, these interventions can be useful for reduc-
ing ADHD-related problems (MTA Collaborative 
Group, 1999). Alternatively, if the family or child is 
unable to participate in behavioral/psychosocial 
interventions, for whatever reason, medication might 
be the most viable initial treatment. 
3. How severe are the child's current symptoms? In 
some cases, the child's behavior is so unmanageable 
or distressing to the family that medication may be 
the fastest and most effective manner of dealing 
with the crisis until other forms of treatment can 
commence. Once the child progresses with other 
therapies, some effort can be made to reduce or ter-
minate the medication, although this is not always 
possible. 
4. Can the family afford the medication and associated 
costs ( e.g., follow-up visits)? Long-term compliance 
rates typically are poor and may be especially prob-
lematic among families with limited financial 
resources. It also may be difficult for these families 
to participate fully in alternative treatments because 
of financial or other constraints, and this also should 
be taken into consideration 
5. Are the parents able to adequately supervise the use 
of the medications and guard against their abuse? 
Some assessment of family functioning and parental 
monitoring should be undertaken to ensure safe and 
appropriate handling of medications. 
6. What is the parent's attitude toward pharmacother-
apy? Some parents simply are "anti-drug" and should 
not be coerced into agreeing to this form of treatment. 
7. Does the household include a substance-abusing sib-
ling or drug-abusing parent? If so, stimulant med-
ication should not be prescribed because of the high 
risk for its illicit use or sale. A sustained-release stim-
ulant medication might be considered, as this type 
has been shown to have lower potential for abuse 
(e.g., Kollins, Rush, Pazzaglia, & Ali, 1999). Cylert 
also might be considered because it seems to have 
little or no street value or potential for abuse. Finally, 
alternative medications such as the antidepressants 
or hypotensive agents might be considered. 
8. Does the child have any history of tics, psychosis, or 
thought disorder? If so, the stimulants should be 
used with more caution, lower starting doses, and 
more careful monitoring. For some children with 
these disorders, the stimulants are contraindicated 
because they exacerbate such difficulties. Other non-
stimulant medications should be considered. 
9. Is the child highly anxious, fearful, or likely to com-
plain of psychosomatic disturbances? Children with 
these characteristics may be less likely to respond 
positively to stimulant medications and may have a 
better response to antidepressant or antihypertensive 
medications. 
10. Does the physician have the time to monitor medica-
tion effects properly? In addition to an initial assess-
ment of drug efficacy and establishing the optimal 
dosage, periodic reassessment of drug response is 
necessary to maximize effects. 
11. How does the child feel about medication and its 
alternatives? With older children and adolescents, 
the medication has to be discussed with them, and its 
rationale fully explained. If children are "anti-drug" 
or oppositional, they may resist efforts to use the 
medication (e.g., refuse to swallow the pill). 
12. Is this child or adolescent involved in competitive 
sports in which urine screens for illicit drug use are 
routine? If so, the clinician should discuss this with 
the parents, as some children may be disqualified 
from participating in competitive sports as a result of 
taking Ritalin immediately prior to or during com-
petitive events. 
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13. Is the older adolescent being considered for medica-
tion treatment planning to enter the military? In a 
number of reported instances, teenagers planning to 
enlist in the U.S. military have been denied admis-
sion because of a history of having ADHD and, in 
particular, of having been treated with stimulant 
medication within the past few years. Again, clini-
cians should discuss this issue with parents and the 
adolescent before initiating stimulant-medication 
treatment. Information from the branches of the mil-
itary suggests that use of medication in childhood 
may not disqualify a young adult from military ser-
vice but taking such medication within a few years of 
enlistment could do so (Hathaway, 1997). 
Once these questions have been addressed adequately 
and a decision has been made to prescribe medication, the 
next step is to begin an appropriate dosing regimen and 
establish a systematic framework in which to evaluate the 
drug effects. The methods that practicing clinicians use to 
monitor response to medication vary widely in content and 
quality. Unfortunately, all too frequently, titration of dosage 
and long-term assessment of efficacy are based solely on the 
subjective reports of parents, thereby increasing the chances 
of erroneous decisions. Indeed, the most appropriate clinical 
dosage for a child cannot be established adequately without 
school-based information, which can be obtained directly or 
via the parent, teacher, and standardized rating scales. 
Bearing heavily on this issue are results from the MTA 
study. This study demonstrated that structured management 
of medication, involving monthly visits to the clinic and col-
lection of objective data from parents and teachers on a reg-
ular basis, was significantly more effective in treating 
ADHD than an approach that was less structured and 
involved less frequent contact between the physician and the 
parent and child (MTA Cooperative Group, 1999). To 
emphasize-the role of teachers and parents and their com-
munication with physicians was of utmost importance in the 
optimal treatment of children with ADHD. 
The medication management group from the MTA study 
also went through a structured procedure for determining 
the optimal dose of medication for each child. The superior-
ity of this approach highlights the need for objective data 
regarding changes in a child's behavior to be collected 
across several doses given the frequently unique and idio-
syncratic reactions of children to these drugs. Under ideal 
circumstances, a child's optimal dose should be established 
in the context of a double-blind, placebo-controlled assess-
ment paradigm that includes multiple measures collected 
across several settings (home, school, and clinic). 
"Double-blind" refers to the fact that the child and his or 
her parents and teachers do not know whether they are 
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receiving actual medication or a capsule with no medication 
(placebo) on a day-to-day or week-to-week basi . This type 
of evaluation involves not only the aggregation of objective, 
quantitative data regarding a child's treatment response but 
also the use of a placebo control wherein teachers, parents, 
and children do not know the dosage being administered 
(Barkley, Fischer, Newby, & Breen, 1988). In addition, it is 
helpful for the parents and teachers to complete a weekly 
Side-Effects Questionnaire (e.g., Barkley & Murphy, 1998). 
There is a high likelihood of apparent "practice effects" 
on these rating scales between their first and second, and 
possibly later, administrations. Many parent and teacher rat-
ing scales show significant declines in scores between their 
first and second administrations even without intervening 
treatment. Clinicians who give the scales once, begin drug 
treatment, and then give them again a week or two later are 
likely to confuse the drug effects with these practice effects, 
concluding that the medication or that do e of it was helpful 
when it might not have been. Clinicians using these scales 
should give them twice before using them in drug trials and 
use the second administration as the baseline against which 
to measure changes resulting from medication trials. 
Figure 2 outlines recommended steps in a standard dou-
ble-blind placebo medication assessment for stimulant 
drugs. These procedures are appropriate only for the stimu-
lant drugs, whose time course of action and half-life are 
quite short. The procedures for conducting systematic med-
ication evaluations for drugs other than stimulants are some-
what more challenging for a number of reasons. As such, we 
will structure our discussion of evaluating drug effects pri-
marily in the context of stimulant medications. 
More detailed descriptions of double-blind protocols can 
be found in the research literature (e.g., Fischer & Newby, 
1991 ), and we present the basic steps. Once children have 
been properly assessed and a prescription has been written, 
it is important to communicate with a pharmacist who is 
willing to prepare capsules for the double-blind experiment. 
In our experience, most pharmacists are more than willing to 
assist in such an evaluation. Usually, the pharmacist will 
prepare 3 weeks' worth of medication into three separate 
containers, marked "Week l," "Week 2," and "Week 3." 
Although not as comprehensive, a trial involving a relatively 
high dose, a relatively low dose, and placebo is helpful in 
determining optimal response. For example, a physician 
could decide to evaluate the effects of 5 mg Ritalin three 
times daily, 10 mg Ritalin three times daily, and placebo. In 
this case, the pharmacist would prepare one pill bottle with 
21 capsules (3/day for 7 days), each containing 5 mg Ritalin 
and a filler (usually dextrose), another bottle with 15 cap-
sules each containing 10 mg Ritalin and filler, and one bot-
tle containing 21 capsules with only filler. 
The capsules should be opaque and small enough for a 
child to swallow easily (in our experience, size 2 capsules, 
about 1/4 inches diameter and 3/4 inches length, work well) . 
The pharmacist then randomly decides which bottle will be 
administered during which week. Ideally, only the pharma-
cist should be aware of this information and should break 
the blind at the end of the evaluation. In the event of med-
ical problems or significant side effects, the blind should be 
broken immediately. 
During the initial assessment and, preferably, at least one 
more time prior to the beginning of the first week of the 
trial, parents and teachers should complete the forms 
described above. Once the individual coordinating the eval-
uation (e.g., physician, psychologist) has completed and 
gathered this baseline information, the trial may commence. 
Parents should administer one capsule to their children two 
or three times each day at the times the physician specifies. 
At the end of each week, parents and teachers should com-
plete the behavior-ratings and side-effects questionnaires 
and return them to the coordinating individual. This should 
be completed for all 3 weeks. At the end of the third week, 
the person coordinating the evaluation should graph the 
information collected from parents and teachers as shown in 
Figure 3. 
At this time, the coordinator and the physician should 
make a judgment about which dose is best for the child. In 
this case, the best dose would be whatever was prescribed in 
week 3-the ratings of problem behavior were lowest and 
the side effects were not different from the other weeks. At 
this point, the blind should be broken and the pharmacist 
should report the information to all parties. Sophisticated 
techniques for graphing and statistically analyzing data of 
the sort presented in Figure 3 have been described (Swanson 
et al., 1998b ). 
Several points regarding the double-blind medication 
assessment are worth noting. 
• First, if feasible, a third dose of medication may be 
evaluated. The procedures would be identical, thus 
extending the trial by one week. 
• Second, if the best dose was placebo, this might indi-
cate that the child may not respond well to the med-
ication in question. Alternatively, it may be necessary 
to titrate the dosage somewhat to determine if another 
dose (perhaps one in between the lowest dose and the 
placebo) would be effective. 
• Finally, the evaluation as described is appropriate only 
for the comparatively short-acting stimulants. Longer-
acting compounds, such as the antidepressants, usu-
ally involve continuous administration of active med-
ication or placebo for several weeks, at which time 
objective measures are collected and decisions about 
efficacy can be made. 
Decision to use 
medications made 
after thorough 
psychological/medical 
assessment 
.. 
• Prescriptions obtained 
• Pharmacist contacted 
• Capsules prepared 
• Objective measures prepared 
• Baseline data collected (including side 
effects) on at least two occasions 
! 
• Dose Level 1 administered (usually two or 
three times daily) 
• Objective measures (parent/teacher) collected 
at week's end 
• Side effects data collected at week's end 
! 
• Dose Level 2 administered (daily) 
• Objective measures (parent/teacher) collected 
at week's end 
• Side effects data collected at week's end 
! 
• Dose Level 3 administered (daily) 
• Objective measures (parent/teacher) collected 
at week's end 
• Side effects data collected 
• Data compared 
• Decision made regarding efficacy to maxi-
mize clinical effects/minimize side effects 
• Blind broken 
• Decision made to further titrate, prescribe, or 
discontinue medication 
Note: "Dose levels" refer to a high dose, low dose, and placebo. 
FIGURE 2 
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Prior to initiating trial 
Week One 
Week Two 
Week Three 
At the end of 
Week Three 
Steps for a Double-blind Placebo-controlled Evaluation of Stimulant Medication 
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...._ Parent Ratings 
-II- Side Effects 
0 ---'----------------- ------
2 
Week 
FIGURE 3 
3 
Hypothetical Results from a Double-blind, 
Placebo-controlled Medication Evaluation with 
two doses of Drug and Placebo 
Once a child's optimal dosage is established, some, 
preferably all, of the above standardized measures should be 
collected periodically from parents and teachers to evaluate 
the need for dosage adjustments or the onset of side-effects. 
Recall that the best effects were observed in the MTA study 
when contact was made monthly and objective data were 
gathered at this point. If this is not feasible, information on 
side effects, at the least, should be collected monthly to 
ensure the absence of any adverse drug effects. 
Parents should be informed in advance about the pre-
senting symptoms and any serious side effects associated 
with the medication (see Tables 1, 2, and 3). For children 
receiving Cylert, blood should be drawn for liver function 
tests at 6-month intervals, or whenever symptoms prompt 
suspicions, given the findings that this drug rarely and idio-
syncratically affects liver functions adversely. At similar 
intervals, children receiving tricyclic antidepressants should 
be evaluated for cardiac functioning. 
During the course of pharmacotherapy, parents might 
report that formerly effective doses are no longer having 
positive effects. Caution is warranted before deciding to 
increase the level of medication. In the absence of precipi-
tating stressful events, family turmoil, or other medical 
events (such as the use of other medications), the current 
dosage indeed might have become less effective. Careful 
questioning of the parent as to the ways in which the child's 
behavior is different or worse can be useful in making the 
decision. In addition, the child's teacher should be contacted 
to ascertain whether his or her functioning is also impaired 
in the school setting. The parent and teacher questionnaires 
discussed above should be administered and compared to 
previously collected data in an effort to specify which 
behaviors have actually worsened and to quantify the 
amount of behavioral change. After this is done, if there are 
no side effects, a cautious increment in dosage may be 
attempted. 
Once ADHD symptoms have been managed effectively, 
the question of when to discontinue treatment may arise. No 
firm guidelines are in place regarding when to discontinue 
pharmacological treatment, other than a determination that 
it no longer seems to be necessary. Up to 20% of children 
may be able to have medication stopped after a year or so. 
These drugs do not necessarily have to be discontinued at 
the onset of puberty as was once believed, as their efficacy 
with adolescents and adults has been well established 
(Smith, Pelham, Gnagy, & Yudell, 1998; Spencer et al., 
1995). Further, the practice of "medication holidays" and 
taking children off medication during the summer months is 
generally not necessary because these drugs do not have sig-
nificant effects on growth (e.g., Zeiner, 1995). In fact, doing 
so is likely to result in impaired functioning in activities in 
which a child may be engaged during these times, such as 
sports, hobbies, and social interactions. 
Other Issues in the Pharmacological Treatment 
Of Children with ADHD 
Parents, teachers, and other professionals who work with 
children who might be taking medication for behavior prob-
lems also should recognize some of the limitations in our 
understanding of how these drugs work and some areas that 
require further research. We will comment briefly on four 
important issues in this area: predicting individual response 
to medication, evaluating consumer satisfaction with med-
ication, using medication with younger children, and assess-
ing the long-term effects of medication use with children 
who have ADHD. 
Predicting Individual Response to Medication 
As noted, different children respond differently to differ-
ent medications. Moreover, different types of behavior 
exhibited by the same child can be influenced differently by 
the same doses of the same medication. As such, an impor-
tant issue in the proper clinical management of child behav-
ior problems is to determine which medications are most 
likely to be effective for which children, and for which 
behaviors. 
More research by far has been conducted on which chil-
dren respond to stimulant medications compared to the other 
types of drugs discussed. Very little is known about which 
children with ADHD are likely to benefit from drugs other 
than stimulants, although Wellbutrin might be particularly 
well suited for children and adolescents who have conduct 
and substance use problems in addition to their ADHD 
(Riggs et al., 1998). Stimulant medication has been shown 
to be effective in reducing problem behavior for approxi-
mately 75% of children to whom they are prescribed (Swan-
son et al., 1993). Nevertheless, as many as 20% to 30% of 
children initially prescribed stimulants might not display a 
positive response to these medications and might even show 
an increase in behavior problems. 
As noted, our understanding is limited as to which chil-
dren respond well to drugs other than stimulants. A variety 
of factors, however, have been proposed to distinguish chil-
dren with ADHD who would respond favorably to stimulant 
medications (responders) from those who would not (non-
responders) including: psychophysiological factors, neuro-
logical variables, familial characteristics, demographic/ 
sociological factors, diagnostic categories, rating-scale 
scores, psychological profiles, and behavioral characteris-
tics (Barkley, 1976). Behavioral and psychophysiological 
measures related to attention span typically are the most 
reliable predictors of improvement during stimulant-drug 
treatment. The greater a child's inattention, the better is his 
or her reaction to medication (the more pronounced effect 
on attention span; Rapport, Stoner, DuPaul, Birmingham, & 
Tucker, 1985). 
Some studies also have found that the quality of the rela-
tionship between parent and child was a good predictor of 
drug response. The better the mother-child relationship, the 
greater is the response to medication. This is related to the 
findings reported earlier that, for many children, the medica-
tion produces positive changes in the behavior of children 
and their mothers alike. Mothers who are more appreciative 
and rewarding of these initial positive changes in their chil-
dren's behavior while on stimulants possibly produce fur-
ther gains associated with treatment. In support of this, Cun-
ningham and Barkley demonstrated that mothers who were 
more interactive with their children and more rewarding of 
child compliance prior to pharmacotherapy had children 
who showed greater positive changes in behavior as a result 
of treatment with medication ( cf. Barkley, 1981 ). 
Higher levels of restless behavior (e.g., hyperactivity), 
poor motor coordination, younger age, and the absence of 
symptoms of overt emotional disorder predicted better stim-
ulant response among a large sample of children with 
ADHD (Taylor, 1986). Similar reports suggest that children 
who are more anxious or depressed according to parent 
and/or teacher ratings (e.g, Conners Rating Scales) have a 
poorer response to stimulant medications and are less likely 
to exhibit "normalized" behavior as a result of treatment 
(e.g., Pliszka, 1989). 
A later study suggested that measures of academic per-
formance are most useful as targets to predict which children 
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will respond to Ritalin at which doses (Denney & Rapport, 
1999). Those authors argued that, when proper statistical 
techniques are used, the ability of baseline scores of atten-
tion and hyperactivity (such as predicted by Taylor, 1986) to 
predict response to medication is decreased substantially. As 
such, they recommended that academic performance be 
used to adjust dose levels of Ritalin when children are func-
tioning at or below a specified level of impairment. Re-
sponse to medication in children who do not show the same 
level of academic impairment should be evaluated using 
other, more specific, domains of functioning, such as atten-
tion and hyperactivity (Denney & Rapport, 1999). 
For clinical purposes, the current evidence still suggests 
that the younger (but still school-age), more inattentive, less 
coordinated, more hyperactive, less anxious, and less intel-
lectually delayed a child may be, and the better the parental 
management and involvement in care of the child, the better 
the response to stimulant treatment. Moreover, academic 
performance that i impaired substantially could be an even 
better predictor of response to stimulant medication. As 
noted previously, predicting response of ADHD symptoms 
to the other classes of medication is difficult at present and 
warrants more research. 
Consumer Satisfaction 
One might assume that the widespread use of medication 
(especially stimulants) with children who have ADHD sub-
sumes relatively high consumer satisfaction with this 
approach to treatment. Relatively few studies, however, 
have been conducted to document whether parents and 
teachers are indeed satisfied with pharmacotherapy for chil-
dren with ADHD. One study revealed that parents of chil-
dren with ADHD initially rated behavioral intervention as 
more acceptable than the use of medication for ADHD (Liu, 
Robin, Brenner, & Eastman, 1991). This study, however, 
was based on parents' reading a description of a hypotheti-
cal case and the judgments were not based on direct experi-
ence with the interventions. Follow-up data in the same 
study revealed that parents' acceptability of Ritalin 
increased as a function of their knowledge about ADHD 
(Liu et al., 1991). Recall also that parents in the MTA study 
reported higher levels of satisfaction with treatment when a 
behavioral/psychosocial intervention was included (MTA 
Collaborative Group, 1999). 
Other studies have reported that parents typically are 
pleased with the use of medication in treating ADHD in 
children, but that these perceptions often are not congruent 
with the attitudes of the children taking the medication. For 
example, one study reported that in more than 25% of the 
cases in which children were treated with Ritalin, parents 
reported a favorable response to the drug whereas children 
reported a negative response (Efron, Jarman, & Barker, 
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1998). The subjective reports of children, especially those of 
very young children, are likely not as reliable as reports 
from parents and teachers (e.g., Sleator , Ullmann, & vbn 
Neumann, 1982). Nevertheless, given the frequency with 
which medication is used to manage ADHD and other 
behavior and emotional problems in children, more studies 
have to be conducted to determine how the children them-
selves perceive this approach to treatment and whether their 
perceptions are of clinical importance. 
Using Medication with Younger Children 
A study by Zito et al. (2000) documented the growing use 
of prescription medication, especially stimulant drugs, for 
use with preschool children. This pattern is particularly con-
troversial because the package inserts and labeling for these 
medications (especially Ritalin) do not describe their use for 
children in this age range. The federal government has indi-
cated that well controlled, large-scale research into the 
effects of these and other kinds of drugs in very young chil-
dren is a top research priority. 
Although a handful of studies have investigated the effi-
cacy of Ritalin in preschool children (e.g., Barkley, 1988), 
the results of these studies generally have shown that the 
drug is not as efficacious for managing problems associated 
with ADHD. In addition to the need for studies that docu-
ment the safety and efficacy of using medication with 
ADHD preschoolers who have ADHD, information is lack-
ing on how the use of stimulants and other drugs may impact 
development of the nervous system, which is still in its 
important formative stages during the preschool years. 
Assessing Long-term Effects 
Perhaps one of the more controversial issues in treating 
of children with ADHD is the long-term impact of pharma-
cological approaches. As noted, the longest systematic stud-
ies of use of medication with children who have ADHD 
noted continued clinical benefits 14 months after initiating 
treatment (MTA study). Other studies have noted that the 
use of stimulant medication may have long-term protective 
effects against the development of other kinds of problems, 
such as substance abuse (e.g., Biederman et al., 1999). 
Although several other longitudinal studies of children with 
ADHD are ongoing (e.g., Mannuzza et al., 1998; Barkley et 
al., 1991 ), specific long-term effects of use of medication 
have not been evaluated systematically in these samples. 
Another possible long-term side effect specific to the use 
of stimulant medications, though unlikely, is the suppression 
of height and weight gain. Early reports indicated that both 
Ritalin and Dexedrine produced this effect (e.g., Safer, 
Allen, & Barr, 1972). Later studies have found this to be a 
dose-related phenomenon, more prevalent with Dexedrine, 
and to occur primarily within the first year of treatment. The 
loss in weight typically is minimal (1 kg/2.2 lbs. or less), 
and growth or habituation to this effect seem to rebound, 
therefore yielding no appreciable effect on eventual adult 
height or weight (e.g., Zeiner, 1995). 
Effects on growth are thought to be secondary to sup-
pression of appetite and stomach distress produced by these 
drugs, although several studies have indicated that stimu-
lants might have some direct effects on growth hormone lev-
els in the blood (Reeve & Garfinkel, 1991). Thus, a reason-
able conclusion is that any suppression in growth is 
typically minor, is a relatively transient side effect of the 
first year or so of treatment, and has no significant effect on 
eventual adult height or weight for the vast majority of chil-
dren with ADHD. 
Evidence indicates that children with ADHD may be 
somewhat smaller than typical children prior to puberty and 
catch up with typical peers during adolescence, yet growth 
delay is associated with the disorder and not with treatment 
using stimulant (Spencer et al., 1996). As always with group 
studies, however, a few individuals within the group have 
more serious weight loss as a function of stimulant treat-
ment. Being so few in number, they may be averaged out of 
the resulting mean statistics. Consequently, the clinician still 
has to monitor weight and height periodically in children 
who receive stimulant medications and to alter dosage sched-
uling if clinically significant changes occur in these growth 
parameters as a function of treatments using stimulants. 
Again, given the comparative frequency with which 
other kinds of medication (e.g., antidepressants, antihyper-
tensive agents) are prescribed for ADHD and are studied 
formally, little is known about the long-term effects of using 
these kinds of medication with children with ADHD. Future 
research has to focus on the effects of these drugs, the com-
bination of these and other drugs, and the combination of 
medication and behavioral interventions, especially as the 
use of multiple prescription medications becomes more 
widespread in managing childhood behavior problems. 
CONCLUSIONS 
The use of psychoactive medication or its combination 
with behavioral interventions has been shown consistently 
to be the most effective approach to managing ADHD. The 
manner in which the medication is used, however, is critical 
to optimize clinical efficacy and minimize side effects. 
Especially important is the regular input of teachers and par-
ents. The MTA Collaborative Study (1999) noted that "sys-
tematic and regular feedback from teachers [does] not seem 
to be part of routine pediatric ADHD treatment practices, and 
may have enhanced the effectiveness of [the study's] med-
ication management" (p. 1081 ). Implicit also in this study 
were structured, monthly meetings and communication 
between parents and health-care providers, a practice often 
not followed in the routine treatment of ADHD. We hope that 
better understanding of some of the relevant issues involved 
with use of medication for ADHD will facilitate communi-
cation among teachers, parents, and physicians in a manner 
that maximizes the chances for effective treatment. 
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